Omeros reported $-32.23M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 37.82M 7.51M Jun/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Cytokinetics USD -190.07M 8.69M Sep/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
MacroGenics USD 19.52M 56.29M Jun/2026
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD 3.24B 3.49B Sep/2026
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
United Therapeutics USD 258.6M 74.4M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026